- $34.07bn
- $33.26bn
- $5.65bn
Brief: Resmed Launches Sleep Institute To Elevate Sleep Health As A Global Priority
Brief: Obstructive Sleep Apnea Expected To Affect Nearly 77 Million US Adults By 2050, New Resmed Study Finds
Brief: Resmed Announces Election Of Nicole Mowad-Nassar To Board, Upcoming Retirement Of Rich Sulpizio
ResMed's Australia-listed shares hit record high on strong earnings
ResMed's Australia-listed shares hit record high on strong earnings
Resmed Inc reports results for the quarter ended June 30 - Earnings Summary
Resmed beats quarterly profit estimates on strong demand for sleep devices
Brief: Resmed Q4 Adjusted EPS USD 2.55 Vs. IBES Estimate USD 2.48
U.S. STOCKS ON THE MOVE-Tesla, Levi Strauss, BioNTech
ResMed falls after rival's sleep apnea drug succeeds in late-stage study
Australia's ResMed slips after rival Apnimed posts positive clinical trial results
U.S. STOCKS ON THE MOVE- PepsiCo, Procter & Gamble
ResMed rises after slight quarterly profit beat
ASX-listed ResMed jumps on better-than-expected Q3 results
ResMed slightly beats quarterly profit estimates, shrugs tariff concerns (updated)
ResMed slightly beats quarterly profit estimates on sleep devices demand
Resmed Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Resmed Q3 Adjusted EPS USD 2.37 Vs. IBES Estimate USD 2.36
ASX-listed ResMed slips after Jarden cuts PT